Eupraxia Pharmaceuticals Inc

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxias product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxias lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved...

Eupraxia pharmaceuticals inc operates in the Biotechnology industry.

Eupraxia pharmaceuticals inc's revenue is 11m - 100m

Eupraxia pharmaceuticals inc has 11 - 50 employees.